Enlivex Therapeutics Ltd. (NASDAQ:ENLV) was the target of a large increase in short interest in December. As of December 31st, there was short interest totalling 5,000 shares, an increase of 11.1% from the December 15th total of 4,500 shares. Based on an average trading volume of 42,000 shares, the short-interest ratio is currently 0.1 days. Approximately 0.1% of the company’s stock are sold short.

Separately, HC Wainwright initiated coverage on Enlivex Therapeutics in a research report on Thursday, January 9th. They issued a “buy” rating and a $20.00 price objective on the stock.

Shares of Enlivex Therapeutics stock traded down $0.52 during trading hours on Thursday, hitting $8.60. 300 shares of the company’s stock traded hands, compared to its average volume of 17,528. Enlivex Therapeutics has a 12-month low of $6.25 and a 12-month high of $44.90. The firm has a market cap of $94.31 million, a PE ratio of -6.15 and a beta of 1.58.

Enlivex Therapeutics (NASDAQ:ENLV) last announced its earnings results on Thursday, November 14th. The company reported ($0.23) earnings per share (EPS) for the quarter. As a group, equities analysts forecast that Enlivex Therapeutics will post -1.06 EPS for the current fiscal year.

About Enlivex Therapeutics

Enlivex Therapeutics Ltd., a clinical stage immunotherapy company, engages in developing allogeneic drugs for immune system rebalancing. Its product candidate is Allocetra, an immunotherapy candidate for the prevention of complications post bone marrow transplantations; treatment of patients that do not respond to steroid treatment upon occurrence of graft vs host disease post bone marrow transplantations; and prevention of cytokine storms, organ damage, and multiple organ failure in sepsis patients.

Further Reading: Portfolio Manager

Receive News & Ratings for Enlivex Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Enlivex Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.